Saturday 17 October 2026 Export ROIV’s income statement to Excel — free account

Roivant Sciences Ltd.

In the quarter to June 2026, revenue fell 33.6%, EPS grew 21.2% and free cash flow fell 30.0%, each against the same quarter a year earlier.

33.53 0.51 −1.50%

Follow ROIV

Alert me

Market cap: $24.6B
P/E: 0.0×
Fwd P/E: −24.0×
Dividend yield: —
F-score: 2/9
Altman Z: 28.31
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 876.48

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	5	10	1	6	2	3	1	7	1	3	4	1

Insider Ownership 27.27%

Capital & Financial Ratios $m

Market Cap 24,590.00

Revenue 7.53

Net Income (414.60)

Free Cash Flow (821.06)

Net Debt (3,842.08)

Current Ratio 16.72

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (24.00)

P/S ratio 3,208.66

P/B ratio 4.91

Past 5Y EPS Growth —

This Y EPS Growth (154.96%)

Next Y EPS Growth 4.98%

Next Y revenue growth 530.75%

Next 5Y EPS Growth 5.61%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 94.76%

10-year low 10-year high

P/B against its own 10 years 82.13%

10-year low 10-year high

EV/Sales against its own 10 years 94.76%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	6,495	4,887	4,292	3,842
Receivables	—	—	770	772
Inventory	—	—	—	—
Other	81	113	105	128
	6,732	5,000	5,167	4,742

	2024	2025	2026	Q'26
Payables	14	24	18	25
ST’ Debt	12	—	—	—
Other	14	1	1	3
	267	149	281	284

Compound Annual Growth %

	10y	5y	3y
Sales	—	(19.07%)	(48.73%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	21.01%	48.76%

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	1	—	—	—	—
’26	2	2	2	3	8
’25	8	4	9	8	29
’24	22	4	16	—	33
’23	4	13	17	27	61
’22	8	14	24	9	55

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(271)	—	—	—	—
’26	(204)	(186)	(196)	(164)	(750)
’25	(193)	(267)	(207)	(173)	(839)
’24	(250)	(196)	(210)	(108)	(765)
’23	(252)	(190)	(223)	(179)	(843)
’22	(141)	(121)	(268)	(147)	(678)
’21	—	—	—	(106)	(552)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(271)	—	—	—	—
’26	(208)	(194)	(192)	(165)	(759)
’25	(194)	(268)	(209)	(173)	(844)
’24	(250)	(197)	(211)	(109)	(767)
’23	(260)	(193)	(223)	(181)	(856)
’22	(144)	(123)	(275)	(154)	(695)
’21	—	—	—	(110)	(558)

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.26)	—	—	—	—
’26	(0.33)	(0.17)	(0.38)	0.52	(0.54)
’25	0.12	(0.31)	0.23	(0.29)	(0.24)
’24	(0.38)	(0.40)	6.03	(0.19)	5.23
’23	(0.48)	(0.42)	(0.49)	(0.05)	(1.42)
’22	(0.16)	(0.32)	(0.41)	(0.39)	(1.26)
’21	—	—	—	(0.87)	(1.43)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	—	9.75	5.80	2.52	6.59	9.69	8.73	20.78	Analyst estimates 2027–2029 Powerpack
	High	—	—	—	10.50	16.76	10.31	13.24	13.06	23.47	42.50
People
People	Employees	—	—	—	—	—	863	904	908	750	721
	Revenue/emp, $m	—	—	—	—	0.00	0.06	0.07	0.04	0.04	0.01
Income, $m
Income, $m	Revenue	—	—	—	—	24	55	61	33	29	8
	Gross margin, %	—	—	—	—	91.36	83.78	78.58	95.11	96.86	84.44
	EBT	—	—	—	0	(899)	(924)	(1,225)	4,568	(682)	(265)
	EBT margin, %	—	—	—	0.00	(3,776.20)	(1,670.85)	(1,998.75)	13,963.43	(2,346.02)	(3,203.12)
	Net income	—	0	—	0	(900)	(924)	(1,115)	4,231	(357)	(398)
	Depreciation	—	—	—	—	—	6	19	22	14	3
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.04	0.08	0.09	0.04	0.04	0.01
	Earnings	—	—	—	(0.01)	(1.43)	(1.26)	(1.42)	5.55	(0.24)	(0.43)
	Cash flow	—	—	—	0.00	(0.88)	(1.01)	(1.18)	(0.98)	(1.16)	(1.08)
	Capex	—	—	—	0.00	(0.01)	(0.03)	(0.02)	0.00	(0.01)	(0.01)
	Free cash flow	—	—	—	0.00	(0.89)	(1.04)	(1.20)	(0.98)	(1.16)	(1.09)
	Book value	—	—	—	7.75	3.24	3.04	2.26	8.23	7.15	7.63
	Shares, m	—	—	—	51	630	670	713	783	725	694
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	1.93	0.00	0.00
	P/S	—	—	—	—	258.96	59.84	85.84	249.73	251.93	2,326.88
	P/B	—	—	—	—	3.02	1.62	3.27	1.27	1.41	3.63
	EV/Sales	—	—	—	—	176.49	26.38	65.27	64.71	94.86	1,846.48
	EV/FCF	—	—	—	—	(7.53)	(2.10)	(4.67)	(2.76)	(3.27)	(20.11)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	0	(552)	(678)	(843)	(765)	(839)	(750)
	Capex	—	—	—	—	(6)	(17)	(13)	(1)	(5)	(8)
	Free cash flow	—	—	—	0	(558)	(695)	(856)	(767)	(844)	(759)
Balance, $m
Balance, $m	Working capital	—	—	—	1	1,968	1,962	1,526	6,465	4,851	4,886
	Total debt	—	—	—	—	170	210	416	443	—	—
	Net debt	—	—	—	(2)	(1,962)	(1,850)	(1,261)	(6,052)	(4,887)	(4,292)
	Shareholders’ equity	—	—	—	398	2,040	2,039	1,608	6,449	5,187	5,292
Returns, %
Returns, %	ROA	—	—	—	(0.19)	(53.90)	(32.67)	(40.57)	90.49	(2.72)	(5.38)
	ROIC	—	—	—	0.00	(868.68)	(448.00)	(211.69)	709.46	(208.81)	(32.17)
	ROE	—	—	—	0.00	(66.40)	(41.45)	(55.34)	107.97	(2.96)	(5.72)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 1 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ONC BeOne Medicines Ltd. - Sponsored ADR	$39.0B	62.6×	40.2×	+29.63% (above 0%: growing)	+143.68% (above 0%: growing)	+117.92% (above 0%: growing)	89.76%	19.06%	Compare
RPRX Royalty Pharma PLC	$34.3B	42.3×	21.9×	+16.50% (above 0%: growing)	−40.00% (below 0%: shrinking)	+31.57% (above 0%: growing)	100.00%	19.75%	Compare
ALNY Alnylam Pharmaceuticals, Inc.	$31.3B	39.5×	39.6×	+66.86% (above 0%: growing)	n/m	+152.82% (above 0%: growing)	76.88%	17.93%	Compare
ROIV Roivant Sciences Ltd.	$24.6B	— (loss-making)	— (loss-making)	−33.55% (below 0%: shrinking)	n/m	−29.99% (below 0%: shrinking)	80.31%	(25,380.93%)
INCY Incyte Corporation	$23.0B	13.9×	15.6×	+37.72% (above 0%: growing)	+39.71% (above 0%: growing)	+1,829.52% (above 0%: growing)	93.73%	41.69%	Compare
BNTX BioNTech SE Sponsored ADR	$22.7B	— (loss-making)	— (loss-making)	−58.53% (below 0%: shrinking)	n/m	−342.04% (below 0%: shrinking)	8.14%	(897.82%)	Compare
GMAB Genmab A/S Sponsored ADR	$22.6B	29.1×	21.0×	+24.86% (above 0%: growing)	−9.26% (below 0%: shrinking)	−7.69% (below 0%: shrinking)	92.73%	32.47%	Compare
INSM Insmed, Inc.	$21.7B	— (loss-making)	— (loss-making)	+296.11% (above 0%: growing)	n/m	+54.52% (above 0%: growing)	84.20%	(0.36%)	Compare
EXEL Exelixis, Inc.	$15.6B	18.8×	16.7×	+10.63% (above 0%: growing)	+25.00% (above 0%: growing)	+557.25% (above 0%: growing)	96.71%	39.51%	Compare
Median of peers	$22.8B	34.3×	21.5×	+27.24%	+25.00%	+86.22%	91.25%	19.41%

All 614 Biotechnology stocks →

Roivant Sciences Ltd. (ROIV) key facts

Roivant Sciences Ltd. (ROIV) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ROIV traded at $33.53, a market capitalization of $24.6 billion.
Return on equity was −5.72% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 28.31 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 1, 2026.